[Vaccination against human papillomavirus and against the cellular proliferation that it induces: facts and expectations].
Vaccination against human papillomavirus (HPV) give promising results in animal models. Prophylactic vaccination uses essentially virus-like particles autoassembled from the L1 capsid protein in its native form. Protection is achieved: it is efficient, type-specific and humoral. Therapeutic vaccination is of cellular origin and raised against the E7 oncoprotein. Several vaccine preparations have been found to be efficient: they include virus-like particles formed with L1-E7 fusion protein, E7 encoding plasmidic DNA, dendritic cells pulsed with E7-derived peptides,.
Giannouli
C
C
Chimie Biologique, Institut de Biologie et de Médecine Moléculaires, Université Libre de Bruxelles, 12 rue des Professeurs Jeener et Brachet, 6041 Gosselies, Belgique.
Burny
A
A
Hallez
S
S
D000818:Animals; D006801:Humans; D051379:Mice; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control*; D014412:Tumor Virus Infections / Q000517:prevention & control*; D014614:Vaccines, Synthetic; D014765:Viral Vaccines
D014614:Vaccines, Synthetic; D014765:Viral Vaccines